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Protein palmitoylation, a reversible lipid modification
of proteins, is widely used in the nervous system,
with dysregulated palmitoylation being implicated
in a variety of neurological disorders. Described
below is ABE/SILAM, a proteomic strategy that
couples acyl-biotinyl exchange (ABE) purification of
palmitoyl-proteins to whole animal stable isotope
labeling (SILAM) to provide an accurate tracking of
palmitoylation change within rodent disease models.
As a first application, we have used ABE/SILAM to
look at Huntington’s disease (HD), profiling palmitoy-
lation change in two HD-relevant mousemutants: the
transgenic HD model mouse YAC128 and the hypo-
morphicHip14-gtmouse, which has sharply reduced
expression for HIP14 (Zdhhc17), a palmitoyl-trans-
ferase implicated in the HD disease process. Rather
than mapping to the degenerating neurons them-
selves, the biggest disease changes instead map to
astrocytes and oligodendrocytes (i.e., the supporting
glial cells).
INTRODUCTION
Protein palmitoylation, the thioesterification of fatty acyl moieties
(often, the saturated 16C palmitate) to selected cysteines, serves
both for tethering proteins to membranes and for in-bilayer
localizations to membrane microdomains. For many proteins,
palmitoylation is reversible, allowing dynamic regulation of pro-
tein-membrane localization. Palmitoylation is widely used at
the neuronal synapse (Conibear and Davis, 2010; Fukata and
Fukata, 2010; Young et al., 2012) where, by modulating protein
and receptor content at synaptic membranes, it participates in
regulating synaptic plasticity. Perhaps not surprisingly, dysre-
gulated palmitoylation has been implicated as being causal inChemistry & Biology 20, 1421–143a number of neurological disorders, notably in schizophrenia
and mental retardation, as well as in Huntington’s disease (HD)
and Alzheimer disease (Young et al., 2012). Below, we describe
ABE/SILAM, a proteomic strategy that profiles and quantifies
brain palmitoylation changewithin rodent models of neurological
disease.
ABE/SILAM combines acyl-biotinyl exchange (ABE) purifica-
tion of palmitoylated proteins (Roth et al., 2006; Wan et al.,
2007) with whole animal stable isotope labeling (SILAM; stable
isotope labeling of mammals; McClatchy et al., 2007a, 2007b;
Savas et al., 2012; Wu et al., 2004) to enable precise sample-
to-sample quantification of palmitoylation change. Our prior
application of ABE proteomics to rat brain and rat neuronal cul-
ture identified most all of the known neural palmitoyl-proteins,
plus more than 100 new palmitoyl-protein candidates (Kang
et al., 2008). The ABE neural palmitoyl-proteome, a set of
300 proteins, includes many well-known synaptic regula-
tors—receptors (e.g., AMPA and NMDA glutamate receptors
and G protein-coupled receptors), downstream G protein
signalers (e.g., H- and N-Ras and Ga subunits), as well as the
scaffolding proteins (e.g., PSD-95 and SAP97) that organize
receptors with downstream signalers within the postsynaptic
density. Nonneuronal brain cells, in particular astrocytes and
oligodendrocytes, also are well surveyed by this analysis. These
glial cells, which make up the majority of cells within the brain,
act to support the neuronal circuitry: oligodendrocytes ensheath
neuronal axons in insulating myelin membranes, whereas
astrocytes provide nutritional support. The addition of SILAM,
we expected, would provide our ABE analysis with an internally
controlled, quantitative capacity that would allow palmitoylation
levels on individual palmitoyl-proteins to be comprehensively
monitored across the neural palmitoyl-proteome, providing a
deeper look into the neurological disease process.
As a first ABE/SILAM application, we have targeted HD, where
dysregulated palmitoylation has been suggested to play an
important role (Huang et al., 2010, 2011; Singaraja et al., 2011;
Yanai et al., 2006). HD is a progressive, dominantly inherited
neurodegenerative disease that begins as a movement disorder
due to the early loss of striatal medium spiny neurons (MSNs).4, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1421
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regions leads to cognitive dysfunction and, ultimately, to death.
The HD causal mutation is an expansion of a polyglutamine
stringwithin theN-terminal exon of the disease protein huntingtin
(HTT). Individuals with polyglutamine tracts of <30 are disease
free, whereas those with expanded glutamine tracts of >40 suc-
cumb to disease. HD typically is characterized by a long disease-
free latent period, with overt disease symptoms not becoming
apparent until middle age. Mutant HTT (mHTT), i.e., harboring
an expanded polyglutamine tract, is aggregation prone and
the appearance of large mHTT aggregates within neurons is a
prominent molecular hallmark of progressing disease. Although
mHTT aggregation likely plays some role in disease pathogen-
esis, it is now widely thought that the largest aggregates, by
sequestering mHTT, are primarily protective (Arrasate et al.,
2004; Kuemmerle et al., 1999; Saudou et al., 1998; Slow et al.,
2005). Indeed, despite its simple genetics and three decades
of research, the process by which mHTT induces neuronal cell
death still remains uncertain, with quite a large array of diverse
mechanisms suggested to be the central disease driver. These
include disordered transcription, disordered posttranslational
mechanisms, impaired mitochondrial function, impaired vesicu-
lar trafficking, impaired protein homeostasis, increased excito-
toxicity, and, finally, impaired protein palmitoylation (Ross and
Tabrizi, 2011; Zuccato et al., 2010).
A role for palmitoylation in HD was first suggested by the iden-
tification of huntingtin-interacting protein-14 (HIP14; Zdhhc17)
as a two-hybrid interactor with HTT (Singaraja et al., 2002).
HIP14 is one of the 23-member mammalian DHHC protein acyl
transferase (PAT) family. These PATs exhibit different, as well
as overlapping, specificity for substrate; together, they appear
to mediate the bulk of the protein palmitoylation within the cell
(Fukata et al., 2004; Greaves and Chamberlain, 2011; Huang
et al., 2004; Lobo et al., 2002; Roth et al., 2002, 2006). Recently,
a Hip14-deficient mouse was found to show neuroanatomical,
behavioral, and physiological disease phenotypes that largely
recapitulate those seen in mouse models of HD (Singaraja
et al., 2011). The shared disease phenotypes suggested that
disease mechanisms also might be shared. More specifically,
impaired palmitoylation of HIP14 substrate proteins may drive
neuropathology not only in the Hip14-deficient mouse, but
also perhaps in HD. Here, we use ABE/SILAM to profile palmitoy-
lation both in the Hip14-deficient brain and in the YAC128 HD
model mouse brain, which expresses an mHTT transgene with
a 128-residue glutamine tract. Significant dysregulations are
uncovered in both brains. ABE/SILAM profiling of the Hip14-
deficient brain identifies a number of proteins showing reduced
representations within the ABE palmitoyl-proteome, including
several previously identified HIP14 substrates, namely SNAP-
25, the cysteine string protein (CSP; Dnajc5), and synaptotag-
min-1 (Syt1) (Greaves et al., 2008, 2010; Huang et al., 2004,
2009). More interesting, perhaps, is the YAC128 analysis, which
highlights a prominent role for glial support cells in the HD dis-
ease process, finding brain-wide reductions for palmitoylated
carbonic anhydrase II (CA II), a glial enzyme involved in the
disposal of neuronal CO2 waste, as well as for three central
players of the astrocytic glutamate-glutamine pathway, which
acts to maintain low neural levels of the excitatory neurotrans-
mitter glutamate, thereby reducing the potential for excitotoxic-1422 Chemistry & Biology 20, 1421–1434, November 21, 2013 ª2013ity. Overall, we find ABE/SILAM to be quite an effective tool
that is able to discern even subtle palmitoylation change in the
5%–10% range, which should prove useful in analyzing
palmitoylation dysregulation in other rodent disease models
beyond HD.
RESULTS
ABE/SILAM Analysis
The ABE chemistry substitutes biotin tags for thioester-linked
acyl modifications, allowing the palmitoyl-protein contingent
of the proteome to be affinity purified by streptavidin-agarose
(Drisdel and Green, 2004; Roth et al., 2006). For ABE, denatured
protein extracts are processed through a sequence of three
chemical treatments: (1) N-ethylmaleimide-mediated blockade
of free thiols, then (2) cleavage of thioester linkages with neutral
pH hydroxylamine to uncover acylation site thiols, (3) which
then are marked with the thiol-specific biotinylation reagent N-
[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide (biotin-
HPDP). SILAM applies the powerful quantitative advantages of
stable isotope labeling, which have been widely employed in
cell culture analysis (Oda et al., 1999; Ong et al., 2002), to the
whole animal (either mouse or rat; McClatchy et al., 2007a,
2007b; Wu et al., 2004). The analysis below uses mice, wholly
labeled with 15N, generated by raising postweaned mice for
10 weeks on a diet in which the nitrogen component is exclu-
sively derived from 15N-labeled Spirulina. Greater than 95%
of brain proteins within these reference mice are 15N labeled
(Adibekian et al., 2011).
The first ABE/SILAM step is a 1:1mixing of brain homogenates
from a 14N test mouse and the 15N reference mouse. The ABE
purification is a multistep, multiday protocol (Roth et al., 2006;
Wan et al., 2007). The prior homogenate mixing is key to elimi-
nating the experimental error that would otherwise accumulate
during the subsequent ABE protocol. Together in the same test
tube, 14N and 15N proteins are subject to exactly the same
experimental forces throughout the ABE purification. After
the ABE purification, the mixed samples are proteolyzed and
subjected to MS/MS (tandem mass spectrometry) analysis.
Because 14N- and 15N-labeled peptides differ by predictable
mass differences, the relative contributions of the 14N and 15N
animals can be deconvolved by a downstream data analysis
(Park et al., 2008). Each identified peptide provides a quantitative
data point that compares the amount of protein present within
the test animal palmitoyl-proteome to its presence within the
reference palmitoyl-proteome (Figure 1A). Abundant palmitoyl-
proteins are typically identified by multiple peptides per MS/
MS run, thus providing multiple reinforcing measurements.
Hip14-gt Brain Palmitoyl Profile
We first used ABE/SILAM to analyze brain palmitoylation change
within the recently characterized Hip14-deficient mouse, which
is homozygous for a gene-trapped allele of Hip14 (Hip14-gt;
Singaraja et al., 2011). Hip14 protein expression is reduced
by >90% in the Hip14-gt mouse brain (Singaraja et al., 2011).
Our comparison of Hip14-gt mouse brain palmitoylation to
isogenic, wild-type (WT) littermates relied on the analysis of eight
14N/15N, ABE-purified samples, with four samples (three bio-
logical replicates plus one technical replicate) being analyzedElsevier Ltd All rights reserved
AB
Figure 1. Example Data for Flottilin-1 from the ABE/SILAM Analysis
of Palmitoylation in Hip14-gt and WT Littermate Brains
(A) Example chromatograms are shown for two Flottilin-1 (Flot1) peptides from
a 14N/15N-WT sample run (left) and from a 14N/15N-Hip14-gt sample run
(right). Each chromatogram compares the abundance of the 14N test peptide
(red trace) deriving from either the WT littermate (left) or Hip14-gt animal (right)
with the corresponding 15N reference peptide (black trace). The ratio of the
peak volumes for the test and reference peptides is reported below.
(B) Graphical summary of the ABE/SILAM peptide data for Flot1 for the eight
MS/MS runs that comprise the Hip14-gt analysis. For the two test genotypes
analyzed,Hip14-gt andWT littermate, four mixed 14N/15N-ABE samples were
prepared from three mice (m1, m2, and m3) plus one technical replicate (m1-
t2). 14N/15N peak ratios for each Flot1 peptide, identified from each MS/MS
run, are reported. At right, the data aggregated from the four component MS/
MS runs are shown with the median value and standard deviation indicated
(***p = 4 3 1012). See related Figure S1.
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The Hip14-gt and WT littermate mice were raised on typical
mouse chow and thus are, in essence, 14N labeled. Rather
than being the control, the 15N-mouse component of each sam-
ple instead provides an invariant reference palmitoyl-proteome,
allowing the amount of each purified 14N-palmitoyl-protein to be
measured against a reference level of 15N-palmitoyl-protein.
The comparison of interest, i.e., between Hip14-gt andWT litter-
mates, is assessed by a ratio of ratios approach that compares
averaged 14N/15N ratios for each protein for the two test
mice. Note that in this triangulated scheme, the 15N reference
mouse need not be of the same age or strain background as
the Hip14-gt and WT test mice.
Figure 1B reports peptide datapoints mapping to the protein
flotillin-1 (Flot1) from each of the eight component MS/MS runs
comprising the Hip14-gt/WT analysis. The individual peptide
datapoints, although showing some scatter, do normally
distribute around median values (Figure 1B). These median
values clearly differ for the Hip14-gt and the WT sample runs,
indicating a reduced presence for palmitoylated Flot1 in Hip14-
gt relative to WT brain. Aggregation of like data sets (Figure 1B,
at right) leads us to conclude that palmitoylated Flot1 is reducedChemistry & Biology 20, 1421–143by 36% in Hip14-gt brain relative to WT brain. Indeed, Flot1 is
one of the proteins showing the greatest and most significant
change in Hip14-gt brain.
The above-noted scatter for the peptide ratio data (Figure 1B)
is not a consequence of the extensive ABE sample processing,
since a similar degree of datapoint variance is also seen for
minimally processed 14N/15N samples, generated by a simple
mixing of 14N and 15N brain homogenates (i.e., no ABE purifica-
tion; Figure S1 available online). In order to overcome uncertainty
due to this scatter, we have focused our analysis on the most
abundant proteins within the ABE palmitoyl-proteome; that is,
proteins like Flot1 (Figure 1B) that are identified on average by
five or more quantifiable peptides per MS/MS run (see Experi-
mental Procedures). For the Hip14-gt/WT analysis, this consists
of the set of 300 relatively abundant palmitoyl-proteins (Table
S1). The vast majority of these proteins do not show substantial
change in Hip14-gt versus WT brain; however, 19 proteins do
show significant change that is >10% in magnitude (Table 1
and Figure S2). Indeed, in addition to Flot1, we find that the
Flot1 paralog, Flot2, also is 36% reduced in Hip14-gt brain.
Flot2 is sufficiently diverged from Flot1 (50% identity) to be
identified here fully independently (i.e., by a nonoverlapping
set of peptides). The two flotillins share roles in endocytosis
and in plasma membrane microdomain formation (Cremona
et al., 2011; Frick et al., 2007; Gkantiragas et al., 2001; Glebov
et al., 2006; Morrow et al., 2002).
The ABE/SILAM data also have been analyzed for the putative
HIP14 substrates that have been identified by prior reports
(Table 1), either by in vitro palmitoylation assays (i.e., utilizing
purified substrate protein and HIP14 enzyme) or by enhanced
palmitoylation in cells, cotransfected together with HIP14 and
the putative substrate protein (Huang et al., 2004, 2009; Ohyama
et al., 2007). Six of these eight proteins are well covered by our
ABE/SILAM analysis (Table 2 and Figure S2). Three, namely
Syt1, CSP (Dnajc5), and SNAP-25, show small but significant
reductions within Hip14-gt brain context of 7%, 8%, and 5%,
respectively. For Syt1 and CSP, the high significance of these
changes (p = 5 3 105 and 5 3 104, respectively) provides an
indication of the power of this approach in discerning even quite
subtle change (Figure S2).
Overall, the palmitoylation change detected in Hip14-gt brain
is less pronounced than anticipated. The two best hits, Flot1
and Flot2, are reduced by only 36% (Table 1). Furthermore, in
contrast with our prior analysis of palmitoylation in yeast strains
knocked out for the different DHHC PATs (Roth et al., 2006), no
protein within our abundant palmitoyl-protein set is found to be
fully lost from the Hip14-gt palmitoyl-proteome, suggesting
that none of these proteins is fully reliant upon HIP14 for palmi-
toylation. In part, this relatively mild palmitoylation defect likely
reflects the well-documented specificity overlaps among the
DHHC PATs (Fukata et al., 2004; Greaves et al., 2010; Hou
et al., 2009; Huang et al., 2009; Roth et al., 2006). Furthermore,
the Hip14-gt allele may allow some leaky expression of WT
HIP14 gene product. Although the gene-trap moiety, inserted
within HIP14 intron-5, is designed for efficient gene product
truncation, any residual, low-efficiency splicing around the
gene trap moiety will yield wild-type enzyme, potentially damp-
ening the magnitude of the Hip14-gt palmitoylation defect. Prior
immunoblot analysis indicated HIP14 expression to be reduced4, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1423
Table 1. Palmitoyl-Proteome Change in Hip14-gt versus WT Brain
Gene Symbol Description Change (%) Reference
Proteomics
ABE Click
Down in Hip14-gt
Flot1 Flotillin 1; endocytosis; plasma membrane microdomain
formation
36*** Morrow et al., 2002 + +
Flot2 Flotillin 2; endocytosis; plasma membrane microdomain
formation
36*** Neumann-Giesen
et al., 2004
+ +
Arhgap21 GTPase-activating protein (GAP) for Cdc42 30** +
Ank2 Ankyrin 2; links integral membrane proteins to
cytoskeleton; membrane domain role
22**
Syn2 Synapsin 2; associates with cytosolic face of synaptic vesicles 18***
Gnal Ga(olf); Ga olfactory type; stimulates adenylyl cyclase 17*** Linder et al., 1993 +
Sept8 Septin 8; GTPase that, together with other septins, forms
filamentous, cytoskeletal structures that demarcate polarized
plasma membrane structures; neuronal polarity
13** +
Camkv CAM kinase-like vesicle-associated 11** +
Fasn fatty acid synthase (ABE detection may reflect thioester
utilization by acyl-carrier function)
10*** + +
Cnp cyclic nucleotide phosphodiesterase; highly concentrated
in myelin sheaths
10*** Agrawal et al., 1990 + +
Gdi2 guanosine diphosphate dissociation inhibitor; Rab GDI beta 10*** +
Up in Hip14-gt
Pde2a cyclic nucleotide phosphodiesterase, cGMP activated +25*** Russwurm et al., 2009 +
Glul GS +12*** +
Lower significance
Add1 adducin 1; a-adducin; heterodimer with g-adducin;
membrane-cytoskeleton associated; promotes assembly
of actin/spectrin network; binds calmodulin
19*
Slc44a1 CTL1; choline transporter-like 1; multi-pass membrane
protein; component of mitochondrial outer membrane;
may be involved in myelin synthesis
15* +
Rap2a small RAS family G protein; regulates dendrite extension
and arborization; farnesylated and palmitoylated
14* Be´ranger et al., 1991 + +
Mtap1b microtubule-associated protein; role in neurite outgrowth 13* +
Gpd2 glycerol-3–phosphate dehydrogenase 2; mitochondrial
inner membrane localization
11*
Pfkl phosphofructokinase, liver 10*
The proteins showing significant change of >10% in the Hip14-gt brain palmitoyl-proteome relative to the WT brain palmitoyl-proteome are listed.
The three rightmost columns provide the published evidence supporting palmitoylation for each protein, including either a specific reference and/or
a ‘‘+’’ indication that the protein was identified as likely palmitoylated in prior ABE- or click-based proteomic analyses (see Table S1 for the specific
references to these proteomic studies and for the expanded ABE/SILAM data set). See Figure S2 for graphical depictions of the peptide data for the
proteins reported within this table. Significance levels: *p < 0.05, **p < 0.01, ***p < 0.001.
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whether Hip14 protein is reduced by 90% or by 99.9% in Hip14-
gt brain, this level of reduction clearly is associated with relatively
severe consequences, as evidenced by the HD-like phenotypes
documented for this mouse (Singaraja et al., 2011).
While Hip14-gt palmitoyl-proteome change is dominated by
reductions, two proteins, glutamine synthetase (GS; Glul) and
the phosphodiesterase Pde2a, show sharply increased levels
within the Hip14-gt palmitoyl-proteome (Table 1; Figure S2). In-
creases could result from a compensative upregulation of other
PATs or, alternatively, could be simply a secondary feature of the
Hip14-gt disease process (Singaraja et al., 2011), i.e., palmitoy-1424 Chemistry & Biology 20, 1421–1434, November 21, 2013 ª2013lation and/or expression changes, secondary to the Hip14-gt-
induced neural injury. Indeed, as is further delineated below,
palmitoyl-proteome change also can be a consequence of
altered expression. Changes in the transcription or the turnover
for a particular palmitoyl-protein obviously will impact the
amount of protein available for purification into the ABE palmi-
toyl-proteome. Palmitoylation and expression-level change
may also be linked in some instances, with impaired palmitoyla-
tion resulting in mislocalization and, consequently, increased
turnover (Valdez-Taubas and Pelham, 2005). A recent proteomic
analysis, which assessed palmitoylation in cells knocked down
for the DHHC PAT DHHC5 (Zdhhc5), found that the vast majorityElsevier Ltd All rights reserved
Table 2. ABE/SILAM Data for Proteins Identified by Prior Work to Be Likely HIP14 Palmitoylation Substrates
Gene Symbol Description Hip14-gt Change (%) YAC128 Change (%)
Dnajc5 CSP; may be involved in Ca2+-dependent neurotransmitter release 8** 7 (ns)
Syt1 synaptic vesicle integral membrane protein; may be Ca2+
sensor for vesicle release
6** 1 (ns)
Snap25 SNAP-25; neuronal SNARE protein that acts together with Vamp2
and Stx1 to effect synaptic vesicle release
5* 7*
Dlg4 PSD-95; SAP-90; membrane-associated guanylate kinase (MAGUK)
scaffolding protein that clusters NMDA glutamate receptors at synapse
5 (ns) 13*
Gad2 GAD-65; glutamate decarboxylase 2; g-aminobutyric acid (GABA)
neurotransmitter biosynthesis; tethers to GABA-containing
synaptic vesicles
+2 (ns) +2 (ns)
Gap43 GAP-43; may play a role in neurite outgrowth and nerve regeneration +7 (ns) +12 (ns)
Htt Huntingtin; disease protein of HD Not detected Not detected
Lck lymphocyte-specific protein tyrosine kinase Not detected Not detected
The change detected inHip14-gt brain palmitoyl-proteome relative toWT brain palmitoyl-proteome is reported for the eight previously identified HIP14
substrates (Huang et al., 2004, 2009; Ohyama et al., 2007). Significance levels: *p < 0.05, **p < 0.001. ns, not significant. See Figure S2 for graphical
depictions of the peptide-level data for the proteins in this table.
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showed reduced expression levels (Li et al., 2012). To assess
the impact of expression-level change on the reduced Flot1
and Flot2 levels measured by ABE/SILAM, we have used immu-
noblot-based quantification to analyze and compare levels of
these two proteins in whole brain homogenates from WT and
Hip14-gt mice (Figure 2A). Significant expression-level reduc-
tions of 43% and 28% are seen for Flot1 and Flot2, respectively,
which is well in line with the 36% reductions found for both by
ABE/SILAM (Table 1). This same immunoblot analysis showed
18% increased expression in Hip14-gt for GS (Figure 2A).
Though not reaching our significance threshold, the upward
trend for GS in this immunoblot analysis is nonetheless again
in line with the highly significant 12% increase seen by ABE/
SILAM (Table 1). Thus, the palmitoyl-proteome change seen
for Flot1, Flot2, and GS appears to be well correlated with
expression-level change. However, as noted above, cause and
effect are not easily parsed. Reduced expression obviously will
reduce the amount of palmitoyl-protein that is available to be
ABE-purified. However, reduced palmitoylation, through effects
on subcellular localization, also may impact protein turnover.
Indeed, in addition to the reduced expression levels found for
Flot1 and Flot2 (Figure 2A), a more focused analysis also finds
reduced levels of palmitoylation per protein in Hip14-gt versus
WT brain homogenates (Figure S3A).
Interestingly, reduced Flot1 and Flot2 palmitoylation also was
highlighted in a recent proteomic analysis of palmitoylation in
neuronal stem cells deficient for DHHC5 PAT (Li et al., 2012).
Furthermore, cotransfection of DHHC5 with Flot2 into COS cells
served to upregulate Flot2 palmitoylation, suggesting that Flot2
likely is a DHHC5 substrate (Li et al., 2012). To test whether the
flotillins might also be HIP14 substrates, we have used the yeast
cell as a context for coexpression of themammalian flotillins with
mammalian HIP14 (Figure 2B). Support for the validity of this
yeast approach is provided by a recent report, which assessed
palmitoylation for several mammalian palmitoyl-proteins, coex-
pressed with a wide panel of the mammalian PATs in yeast
(Ohno et al., 2012). For our analysis, in addition to looking atChemistry & Biology 20, 1421–143Flot1 and Flot2, we also examined SNAP-25, a well-documented
HIP14 substrate (Greaves et al., 2009; Huang et al., 2004, 2009).
SNAP-25, we find, is palmitoylated in HIP14-expressing cells,
but not in DHHC5-expressing cells or in naive yeast cells, not
expressing any mammalian PATs (Figure 2B). In contrast, Flot1
and Flot2 are palmitoylated only in the DHHC5-expressing cells,
not in the HIP14-expressing cells. Thus, at least in yeast, HIP14
is active against SNAP-25, but not the flotillins, whereas both
flotillins are recognized by DHHC5. Therefore, Flot1 and Flot2
appear not to be bona fide HIP14 substrates. The strong reduc-
tions seen for these two proteins in the Hip14-gt palmitoyl-
proteome likely is a secondary manifestation of the Hip14-gt
disease process. As DHHC5 is regulated by a rapid degradative
turnover mechanism (Li et al., 2012), we entertained the pos-
sibility that reduced flotillin palmitoylation might be a con-
sequence of reduced DHHC5 levels in the Hip14-gt brain.
However, our ABE/SILAM analysis does not reveal any major
change in palmitoylated DHHC5 levels in Hip14-gt versus WT
brain (Figure S3B).
ABE/SILAM Analysis of the HD Mouse YAC128
We have also analyzed YAC128, a well-characterized mouse
model of HD that expresses a full-length humanmHTT transgene
containing a 128-residue-long polyglutamine string (Slow
et al., 2003). As with the human disease, the YAC128 mouse
shows a disease-free latent period, with frank disease becoming
evident in terms of striatal atrophy and associated motor
defects at 10-12 months of age. For our ABE/SILAM analysis,
12-month-old YAC128 mice were compared with their WT
littermates. Our analysis again focuses on the abundant
palmitoyl-protein set (Table S2), with the 19 proteins showing
significant change of >10% listed in Table 3. Prominent within
this list are a number of glial-specific proteins, including CA II
(Car2), which is present mainly in astrocytes and oligodendro-
cytes; two myelin-associated oligodendrocyte proteins, the
phosphodiesterase Cnp and the transmembrane protein Mog;
and three well-known components of the astrocyte glutamate-
glutamine pathway, namely GS (Glul) and the two glutamate4, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1425
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Figure 2. Flot1 and Flot2 Expression Levels and DHHC PAT
Specificities
(A) Quantitative immunoblotting was used to analyze expression level
change in Hip14-gt and WT brains for CA II, Flot1, Flot2, and GS. Whole
brain homogenates from Hip14-gt and WT animals were analyzed by
immunoblotting with specific antibodies. SNAP-25 was used as the
normalization control. Example immunoblots are shown at left and quantified
results represented as means ± SD are shown at right (n = 3; *p = 0.01; **p =
0.003).
(B) Analysis of HIP14- and DHHC5-mediated palmitoylation of Flot1 and Flot2
in yeast. Yeast cells were cotransformed with two plasmids, a plasmid that
drives constitutive expression of a DHHC PAT (HIP14, DHHC5, or empty
vector control) and a plasmid for GAL1 promoter-inducible expression of the
test substrate protein (SNAP-25, Flot1, or Flot2). Palmitoylation was assessed
using a click chemistry-based approach in which the expressing yeast cells
were metabolically labeled with the alkynated palmitate analog ODYA, with
substrate and enzyme proteins subsequently anti-FLAG immune precipitated
from protein extracts and, finally, click reacted with azido-Alexa647 to allow
fluorographic detection (see Experimental Procedures). Anti-HA (epitope tag)
immunoblotting was used to monitor the levels of these proteins both within
the immune precipitation (left panel) and within the initial protein extracts (right
panel). See related Figure S3.
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Tracking Brain Palmitoylation Change in HDtransporters GLT-1 (Slc1a2) and GLAST (Slc1a3). GLT-1,
GLAST, and GS act together to limit brain levels of the excit-
atory neurotransmitter glutamate, thus limiting potential excito-
toxicity. GLT-1 and GLAST localize to the astrocytic plasma
membrane, where they act to clear glutamate from excitatory
synapses to the astrocyte cytoplasm where it is converted into
the less-toxic glutamine by GS. Excitotoxicity is implicated as
a key driver of neuronal cell death in many neurodegenerative
disorders, including HD (Lau and Tymianski, 2010; Raymond
et al., 2011). Reduced function of any of these three proteins
(GLT-1, GLAST, or GS) would be expected to enhance the
potential for excitotoxicity. CA II, the protein with the most
prominent YAC128 reduction (Table 3), also likely plays an1426 Chemistry & Biology 20, 1421–1434, November 21, 2013 ª2013important role in maintaining the healthy brain environment.
CA II, the most abundant brain carbonic anhydrase isoform,
accelerates the equilibrium of CO2 and H2O with HCO3
 and
H+ and thus helps to maintain the proper brain acid-base bal-
ance by ridding the brain of the excess CO2 waste produced
by the high rate of neuronal respiration (Deitmer, 2002; Deitmer
and Rose, 2010).
Although ABE/SILAM detection implies palmitoylation, neither
CA II nor GS have yet been definitively reported to be palmitoy-
lated. As a test of this, we have assessed the hydroxylamine
dependence of their ABE purification (Figure 3A). Hydroxylamine
(HAm), with its cleavage of the acyl-cysteine thioester linkage,
plays a central role in ABE. Indeed, parallel minus-HAm reactions
are often employed in ABE proteomic analyses to help distin-
guish palmitoyl-proteins from contaminant proteins that may
purify nonspecifically; bona fide palmitoyl-proteins show HAm-
dependent purification (Kang et al., 2008; Roth et al., 2006;
Wan et al., 2007; Yang et al., 2010). Using the acyl-resin-assis-
ted-capture (acyl-RAC) simplification of the ABE protocol
(Forrester et al., 2011), CA II and GS both show strong, HAm-
dependent purifications indicative of palmitoylation (Figure 3A).
Additional support for GS and CA II palmitoylation can be
gleaned from the published literature: GS was detected in our
large-scale ABE analysis of rat brain palmitoylation (Kang
et al., 2008), whereas CA II was identified as a palmitoyl-protein
in a click-chemistry-based proteomic analysis in mouse brain
(Li et al., 2012). In theory, both enzymes could have their
functionality altered by palmitoylation. Both CA II and GS have
been suggested to participate in membrane-localized meta-
bolons, with import/export efficiency being enhanced by the
direct association of the enzyme with the relevant plasma mem-
brane transporter (Moraes and Reithmeier, 2012). Palmitoylation
may help these enzymes gain access to their cognate mem-
brane-localized transporters. For GS, an association with GLT-
1 and GLAST glutamate transporters would allow for efficient
conversion of glutamate into glutamine as it is brought into the
astrocytes (Moraes and Reithmeier, 2012). Although an inter-
action of GS with these transporters remains undocumented,
some small support for this speculation comes from a colocali-
zation for GS and GLAST at the surface of retinal Muller glial
cells (Derouiche and Rauen, 1995). The CA II metabolon stands
on firmer ground, with CA II documented to associate with
several different plasma membrane bicarbonate and proton
transporters (Li et al., 2002; Loiselle et al., 2004; Sterling et al.,
2002; Vince and Reithmeier, 1998). Localization of such CA II
metabolons to the astrocytic membrane sites that juxtapose
with the cerebral vasculature (i.e., the astrocytic foot) could
facilitate the coupled excretion of respiratory waste products
from the brain.
CA II and GS are generally appreciated to be soluble enzymes,
which reside in the cytoplasm. Palmitoylation may apply to
only a minor, membrane-targeted subpopulation. The current
palmitoylation detection methodologies do not provide infor-
mation regarding palmitoylation stoichiometry, and thus it is
generally unclear whether 90% or only 0.1% of the protein
population is being modified. Here, to investigate this issue, we
have used a modified acyl-RAC protocol (Forrester et al.,
2011). Following the N-ethylmaleimide-mediated thiol blockade
and subsequent HAm-mediated thioester cleavage steps, theElsevier Ltd All rights reserved
Table 3. Palmitoyl-Proteome Change in YAC128 Relative to WT Littermate Brain
Gene Symbol Description Change (%) Reference
Proteomics
ABE Click
Down in YAC128
Car2 CA II; mediates the interconversion of CO2 and H2O to H
+ and HCO3
;
localized in brain mainly to oligodendrocytes and astrocytes
42*** +
Glul GS; converts glutamate to glutamine; role implicated in excitotoxicity;
localized in brain mainly to astrocytes
29*** +
Pde10a cAMP and cGMP 30,50-cyclic phosphodiesterase 10A, cAMP-inhibited;
localized mainly to striatum
27*** Charych et al., 2010 +
Vdac3 voltage-dependent anion-selective channel protein 3; mitochondrial
outer membrane porin
17*** + +
Uqcrc1 cytochrome b-c1 complex protein 1, mitochondrial 16** +
Cnp 20,30-cyclic-nucleotide 30-phosphodiesterase2; localizes to
oligodendrocyte myelin membranes
14*** Agrawal et al., 1990 + +
Atp2b1 PMCA1; plasma membrane calcium-transporting adenosine
triphosphatase 1 (ATPase 1)
14*** +
Atp2b4 PMCA4; plasma membrane calcium-transporting ATPase 4 11** + +
Slc1a2 GLT-1; EAAT2; glial high-affinity glutamate transporter; astrocyte protein;
mediates retrieval of synaptic glutamate; implicated role in excitotoxicity
11** Huang et al., 2010 +
Up in YAC128
Gnas Gas; Ga heterotrimeric G protein component; stimulates adenylyl cyclase +10*** Linder et al., 1993 + +
Lower significance
Igsf8 EWI-2; PGRL; CD316; immunoglobulin superfamily member; interacts
with tetraspannins to regulate cell migration
27* He et al., 2011 + +
Hadhb trifunctional enzyme (hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA
thiolase/enoyl-CoA hydratase), subunit beta, mitochondrial
24* + +
Slc1a3 GLAST; EAAT1; glial high-affinity glutamate transporter; astrocyte protein;
mediates retrieval of synaptic glutamate; implicated role in excitotoxicity
14* +
Dlg4 PSD-95; SAP-90; MAGUK scaffolding protein that clusters NMDA
glutamate receptors at synapse
13* Topinka and Bredt, 1998 + +
Mog myelin oligodendrocyte glycoprotein; IgG superfamily; type 1
transmembrane protein localizing to outer layer of myelin sheath;
auto-antigen in multiple sclerosis; causal mutation in familial
form of narcolepsy
13* +
Gria3 GluR3; GluA3; AMPA glutamate receptor subunit 10* Hayashi et al., 2005 +
Arvcf Armadillo repeat protein deleted in velo-cardio-facial syndrome homolog +33* +
Uba1 ubiquitin-like modifier-activating enzyme 1; ubiquitin E1 enzyme; likely
detected by ABE due to its transient thioester linkage to ubiquitin
+17* + +
Arhgap21 GAP for Cdc42 +11* +
Data are reported for the proteins that show significant change of >10% in the YAC128 palmitoyl-proteome relative to the WT palmitoyl-proteome.
The three rightmost columns provide the published evidence supporting palmitoylation for each protein, including either a specific reference and/or
a ‘‘+’’ indication that the protein was identified as likely palmitoylated in prior ABE- or click-based proteomic analyses (see Table S2 for references to
the relevant proteomic studies and for the expanded ABE/SILAM data set). Proteins that are expressed predominantly in either oligodendrocytes or
astrocytes are underlined. Significance levels: *p < 0.05; **p < 0.01; ***p < 0.001.
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Tracking Brain Palmitoylation Change in HDfraction of the protein population that is available for thiopropyl-
Sepharose-mediated pull-down is assessed. The palmitoylated
subpopulation should bind to the resin and thus be removed,
whereas the nonpalmitoylated subpopulation should remain
unbound. We have examined CA II and GS, along with the two
flottilins, as well as PSD-95 and Gas (Figure 3B). Flot1, Flot2,
PSD-95, and Gas all are efficiently captured, with 70%–90% of
each population being depleted in the plus-HAm condition, but
not in the minus-HAm control condition. Thus, in WT brain, these
proteins appear to be mainly palmitoylated. These results withChemistry & Biology 20, 1421–143the two ‘‘control’’ proteins (i.e., PSD-95 and Gas) are significant
because both proteins are well known to undergo dynamic
palmitoylation, cycling between palmitoylated and depalmitoy-
lated states (Conibear and Davis, 2010), with essentially nothing
known about their basal palmitoylation status in vivo. This
analysis indicates that the palmitoylated forms of these two
proteins predominate. In contrast with the high palmitoylation
stoichiometries seen for four of the six proteins tested, CA II
and GS both are quite poorly depleted by the thiol-Sepharose
resin (Figure 3B), indicating that palmitoylation likely applies4, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1427
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Figure 3. Analysis of CA II and GS Palmitoylation
(A) CA II and GS both show HAm-dependent ABE purification indicative of
palmitoylation. WT mouse brain homogenates were processed through
parallel acyl-RAC purifications, either in the presence or absence of HAm. The
two purified samples were blotted with antibodies specific to the two proteins
(‘‘palm’’).
(B) Fractional palmitoylation was assessed by thiol-Sepharose-mediated
depletion of indicated proteins, after acyl-RAC work-up of WT whole brain
homogenates. As for (A), homogenates were processed through parallel plus-
andminus-HAm protocols, with the portion of the samples that failed to bind to
the thiol-Sepharose (unbound) being compared with the starting homogenate
(input) by immunoblotting with the indicated specific antibodies. See related
Figure S4.
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Tracking Brain Palmitoylation Change in HDonly to a minor population of these two proteins (<10%). Using
the assumption that both the capture by, and elution from, the
thiol-Sepharose affinity resin is 100% efficient, we estimate a
lower limit for the palmitoylation of CA II and GS of 0.5%
(Figure S4), indicating that 0.5%–10.0% of these two protein
populations are palmitoylated. This relatively low palmitoylation
level may yet prove critical for targeting subpopulations of these
enzymes to membranes, perhaps facilitating interaction with
relevant membrane transporters.
The 42% and 29% decreases for CA II and GS detected by
ABE/SILAM in YAC128 brain (Table 3) indicate sharp reductions
for the palmitoylated subpopulations of these two enzymes. To
test whether reduced levels of the palmitoyl forms, might reflect
broader expression level changes, whole brain homogenates
from YAC128 and WT littermate mice were subjected to quanti-
tative immunoblot analysis (Figure 4A). Indeed, CA II and GS
both show reduced expression levels in YAC128 homogenates1428 Chemistry & Biology 20, 1421–1434, November 21, 2013 ª2013that are roughly consistent with decreases seen by ABE/SILAM:
CA II shows a significant 35% reduction (p = 0.017), whereas
the 28% reduction detected for GS (p = 0.13) fell short of our sig-
nificance threshold. Additional support for sharp and significant
expression level reductions for these two proteins is provided
both by a whole proteome SILAM analysis of WT and YAC128
brain homogenates (data not shown), and by immunoblot
analysis of dissected WT and YAC128 brain regions (Figure 4B).
In light of the low palmitoylation stoichiometries detected for
both proteins (Figure 3B), the sharply reduced expression
levels measured here suggest that the large disease-induced
changes detected by ABE/SILAM for CA II and GS are likely
fundamentally the result of disordered expression, not disor-
dered palmitoylation.
In human HD and in the YAC128 model, neuronal cell death is
first evident in the striatum, with progression then to the cortex
and hippocampus and then, finally, to the rest of the brain
(Slow et al., 2003). To analyze the distribution of GS and CA II
expression level changes within the brain, we applied our quan-
titative immunoblot analysis to homogenates of striatum, cortex,
and cerebellum dissected from YAC128 and WT littermate mice
(Figure 4B) at 15 months, which is a relatively late stage in the
YAC128 disease process (Slow et al., 2003). Consistent with
the spreading pathology typically seen at this stage, significant
reductions for CA II and GS are seen in all three subregions,
with the most extreme and significant reductions focused within
the striatum (Figure 4B).
Comparison of Hip14-gt and YAC128 Palmitoyl Profiles
In light of the hypothesis that HIP14 dysfunction plays a causal
role in HD pathogenesis (Singaraja et al., 2011), we were inter-
ested to compare the palmitoylation changes documented
here for Hip14-gt and YAC128 brain. Do the two mice show
similar palmitoylation derangements? For this, the 13 top
Hip14-gt hits (Table 1) were assessed for correlated change in
the YAC128 brain (Figure 5A) and, in a reciprocal analysis, the
10 top YAC128 hits (Table 3) were assessed for correlated
Hip14-gt change (Figure 5B). Overall, palmitoylation derange-
ments for the two mice are not well correlated. Indeed, some
proteins (e.g., Flot2, Arhgap21, Ank2, Gdi2, Gas, and most
notably GS), show significant change that is opposite in sign in
the two mutant palmitoyl-proteomes. For instance, GS shows
a highly significant 29% decrease in the YAC128 palmitoyl-pro-
teome (p = 4 3 105), while showing a significant 12% increase
in the Hip14-gt palmitoyl-proteome (p = 3 3 104). However,
correlated change is seen for some proteins, notably for CA II,
Cnp, and Pde10a. It will be interesting to see whether the pro-
teins within this correlated subset play some driving role in the
shared Hip14-gt/YAC128 pathologies (Singaraja et al., 2011).
In addition, we have examined the Hip14-gt and YAC128 ABE/
SILAM data for eight proteins previously identified as HIP14 sub-
strates (Table 2). Some of these, notably CSP, SNAP-25, and
PSD-95, do show subtle downward trends in both Hip14-gt
and YAC128 brains, consistent with our prior report, which found
HIP14 PAT activity to be reduced in YAC128 brain (Singaraja
et al., 2011). Thus, although HIP14 dysfunction likely plays an
important part in HD pathogenesis (Huang et al., 2011; Singaraja
et al., 2011; Yanai et al., 2006), the absence of a strong correla-
tion between Hip14-gt and YAC128 palmitoyl-proteome changeElsevier Ltd All rights reserved
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(A) Expression-level analysis of CA II and GS in 12-
month-old YAC128 and WT littermate whole brain
homogenates. An immunoblot analysis identical to
that in Figure 1C was employed (WT, n = 2;
YAC128, n = 4).
(B) Brain distribution of CA II and GS expression
reductions. Homogenates from striatum, cortex,
and cerebellum dissected from five 15-month-old
YAC128 and WT littermate brains were subjected
to quantitative immunoblot analysis. Results are
depicted as means ± SD. Significance levels: *p <
0.05, **p < 0.01, ***p < 0.001.
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Tracking Brain Palmitoylation Change in HDsuggests that HIP14 dysfunction is unlikely to be the sole disease
driver.
DISCUSSION
ABE/SILAM
ABE/SILAMbuilds upon our prior ABE/spectral-count-basedMS
approaches that were used, for instance, tomap the yeast palmi-
toyl-proteins with their modifying DHHC PATs (Roth et al., 2006).
The SILAM addition substantially improves quantification: rather
than the 2- to 5-fold differences, discernable by spectral-count-
basedmethods (Roth et al., 2006), ABE/SILAM allows significant
change in the 5%–10% range to be reliably detected. Whereas
ABE/SILAM should prove useful for analyzing other diseases
in which dysregulated palmitoylation is implicated (Cheng
et al., 2009; Mansouri et al., 2005; Mizumaru et al., 2009;
Mukai et al., 2008; Raymond et al., 2007; Tarpey et al., 2009;
Vetrivel et al., 2009), it alsomay prove valuable even when palmi-
toylation is not directly involved. For instance, we have seen that
the proteins showing the biggest palmitoyl-proteomic changes
(e.g., Flot1 and Flot2 in Hip14-gt brain and CA II and GS in
YAC128 brain) also show correlated expression-level change.
In theory, this change also could have been detected by a whole
proteome SILAM analysis, omitting the cumbersome ABE
purification steps. A big advantage of including the ABE purifica-
tion, however, is that it focuses the analysis on just a limited set
of functionally important proteins. MS-based proteomic ana-
lyses tend to be dominated by the most abundant sample
proteins, with abundant housekeeping functions often obscuring
interesting regulatory proteins, typically present at lower stoichi-
ometries. By purifying the palmitoyl-proteome, ABE focuses the
analysis on a much smaller set of proteins, with an outsized reg-
ulatory role. Indeed, the neural palmitoyl-proteome includes
many of the well-known synaptic regulators (e.g., receptors,
G proteins, scaffolds, and SNAREs), the ion channels that
serve to initiate and propagate the nerve impulse, as well as
many of the transmembrane proteins that mediate the cell-cell
adhesions that wire the neuronal circuitry (Kang et al., 2008).
Glial cell regulators, as the present work highlights, also are
well represented. Overall, ABE/SILAM provides a look at
neurological disease that is both detailed and broad.
YAC128 Palmitoyl-Proteome Change
The two proteins showing the most pronounced change in the
YAC128 palmitoyl-proteome are CA II and GS, which wereChemistry & Biology 20, 1421–143reduced by 42% and 29%, respectively (Table 3). Both also
show correlated expression level reductions (Figure 4A). As
only small subpopulations of both enzymes appear to be palmi-
toylated (Figure 3B), it is likely that expression level change and
not dysregulated palmitoylation is mainly responsible for the
reduced ABE/SILAM detection. Indeed, reduced expression
for both proteins has been previously documented in profiling
analysis of other HD mouse models (Deschepper et al., 2012;
Hodges et al., 2008; Kuhn et al., 2007; Luthi-Carter et al.,
2000). Neither enzyme has yet been well studied within the HD
disease process context. Both could well play important roles.
As discussed below, reduced GS activity would be expected
to elevate brain glutamate levels, enhancing excitotoxicity po-
tential. CA II is the most abundant brain carbonic anhydrase,
being predominantly expressed in oligodendrocytes and astro-
cytes, where it likely participates in the excretion of the large
amounts of CO2 waste produced by the high neuronal respira-
tory rate. CO2 diffuses out of neurons and into glial cells, where
it is trapped by its CA II-mediated conversion into the ionic
HCO3
, allowing for vectorial excretion to the circulatory system,
likely by astrocytic bicarbonate transporters. Proper CO2
removal, obviously, is important to avoid toxic acidification. In
humans, CA II deficiency results in marble brain syndrome, a
mental retardation that is part of a wider syndrome that includes
nonneural symptoms, such as osteopetrosis and impaired kid-
ney function (Sly et al., 1983). The substantial brain-wide reduc-
tion in CA-II, reported here, could easily play a major role in the
HD disease process.
Several of our top YAC128 hits have been previously impli-
cated in the HD disease process. Indeed, the cyclic nucleotide
phosphodiesterase Pde10a (Table 3) is emerging as a potential
HD therapeutic target, with the Pde10a-specific inhibitor PF-
02545920 in early clinical trials (http://clinicaltrials.gov/show/
NCT01806896). Pde10a shows sharply reduced transcription
in both a mouse HD model and in human HD brain (Hebb
et al., 2004), and it is likely that the 27% reduction found here
in the YAC128 palmitoyl-proteome is secondary to this expres-
sion reduction. Pde10a has two major isoforms with alternative
N-terminal exons, a cytosolic A1 splice variant that is widely ex-
pressed throughout the brain and a palmitoylated, membrane-
localized A2 splice variant, which localizes primarily to striatal
MSNs, these being the early targets of HD-induced cell death
(Charych et al., 2010; Hu et al., 2004). It is this palmitoylated
striatal A2 variant that is specifically and strongly reduced in
the mouse HD model (Hu et al., 2004). The expression reduction4, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1429
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Figure 5. Correlating the Hip14-gt and YAC128 Palmitoylation
Profiles
(A) Hip14-gt:YAC128 comparison. The thirteen proteins identified with the
most significant ABE/SILAM change in Hip14-gt relative to WT littermates
(from Table 1; red bars) were analyzed for change in YAC128 brain relative to
its WT littermates (blue bars indicate significant change, whereas light blue
bars indicate nonsignificant change). Significance levels: *p < 0.05, **p < 0.01,
***p < 0.001. Proteins are denoted by gene symbol, except for CA II (Car2) and
GS (Glul).
(B) YAC128:Hip14-gt comparison. The ten proteins identified with the most
significant ABE/SILAM change in YAC128 (Table 3; blue bars) were analyzed
for change in Hip14-gt (red bars indicate significant change, whereas change
denoted by light red bars indicate nonsignificant change).
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Tracking Brain Palmitoylation Change in HDis suggested to play an ameliorative role in the disease process,
since drug-mediated inhibition of Pde10a appears to be
neuroprotective in the rat quinolinic acid-induced model of
HD (Giampa et al., 2009).
The GLT-1 (Slc1a2) glutamate transporter has been previ-
ously identified as a potential player in HD pathogenesis,
showing reduced function and expression both in mouse HD
models and in human HD (Arzberger et al., 1997; Behrens
et al., 2002; Estrada-Sa´nchez et al., 2009; Hassel et al., 2008;
Huang et al., 2010; Lie´vens et al., 2001; Nicniocaill et al.,
2001). Indeed, we have previously reported reduced palmitoyla-
tion and transporter function for GLT-1 in YAC128 brain (Huang
et al., 2010). Here, in addition to GLT-1, we also find significant
reductions for two other key players in the astrocyte’s glutamate
retrieval mechanism: GLAST (Slc1a3), a second astrocyte gluta-
mate transporter that also participates in glutamate reuptake
from the synapse, and the astrocytic enzyme GS, which acts
downstream of the transporters to convert the internalized
glutamate into glutamine. Reduced function of any of these pro-
teins would be expected to contribute to excitotoxic stress. The
coreduction of all three together, as we find here in YAC128
brain, provides strong support for excitotoxic models of HD
pathogenesis.1430 Chemistry & Biology 20, 1421–1434, November 21, 2013 ª2013Glial-Specific Change: Cause or Effect?
What is to be drawn from the preponderance of astrocytic and
oligodendrocytic proteins among our top YAC128 hits (Table
3)? Distinguishing the causal change that drives the disease
process from change that may be induced in response to the
initial injury generally is difficult in profiling analyses like the pre-
sent one. Both types of change may be therapeutically relevant.
Interruption of the causal chain provides an obvious therapeutic
strategy. On the other hand, secondary change often is part of
the body’s natural ameliorative response. Thus, inducing or
augmenting these secondary changes presents a second
therapeutic path. The glial change identified here could well be
secondary. Indeed, reactive gliosis, a process that involves
proliferation, migration, and reprogramming of astrocytes, is a
well-known neural response to brain injury (Allaman et al.,
2011). Reactive gliosis can be induced either by trauma or by
neurodegenerative injury and is well documented in HD (Vonsat-
tel et al., 1985). However, downregulation of the glutamate-
glutamine pathway, as is reported here, generally is not part of
the gliotic response (Sofroniew, 2009). Nevertheless, such
changes could well be part of the HD-specific response to
mHTT-induced injury. Alternatively, some of the identified glial
change could be causal. HD is a neurodegenerative disease
and its disease symptomology is best understood as resulting
from neuronal cell death. Thus, over the years, it has made
most sense to look within the neuron for the disease origins.
However, neuronal cell death can also be the result of reduced
glial support. Interestingly, transgenic mice, engineered to ex-
press mHTT exclusively within astrocytes, recapitulate key HD
pathologies (Bradford et al., 2009), whereas mice engineered
to express mHTT in discrete neuronal populations, including
within striatal MSNs, surprisingly, do not manifest HD-like phe-
notypes (Gu et al., 2005, 2007). Thus, impaired glial cell support
could well be a major disease driver. In conclusion, our analysis
lends further credence to models that see mHTT-induced glial
dysfunction as a major contributor to HD pathogenesis.
SIGNIFICANCE
ABE/SILAM tracks palmitoylation change within the whole
animal, providing broad and accurate looks, able to discern
subtle change in the 5%–10% range. With the emerging
connections that now link dysregulated palmitoylation to
neurological disease and cancer, this approach should
help identify the key palmitoylation-dependent targets and
pathways that drive the disease process. Furthermore, as
drugs are developed to modify disease course through inhi-
bition of either the individual palmitoyl-transferases that add
these modifications or the thioesterases that remove them,
ABE/SILAM will provide a way of assessing drug actions
in vivo. Here, the first ABE/SILAM applications to mouse
models of HD highlight both the power and limitations of
this approach. Intriguingly, much of the change identified
in theHDmodelmouse YAC128maps to glial-specific palmi-
toyl-proteins, with major reductions seen for CA II, an
enzyme that helps rid the brain of its otherwise toxic CO2
waste, and also for three well-known regulators of glutama-
tergic excitotoxicity, glutamine synthetase and the GLT-1
and GLAST glutamate transporters.Elsevier Ltd All rights reserved
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ABE/SILAM Proteomic Analysis
The two ABE/SILAM analyses of this report compared brain palmitoyl-pro-
teomes for 3-month-old Hip14-gt mice with their WT littermates (nontrans-
genic siblings) and 12-month-old YAC128 mice with their WT littermates.
These mutant and WT mice were raised on standard mouse chow and thus
are, in effect, 14N labeled. To generate these comparisons, palmitoylation in
the individual mutant and WT test mouse brain were first compared with
palmitoylation in the 15N-labeled reference mouse brain, these mice being
WT C57Bl/6 mice raised on a diet for which the protein component was
comprised exclusively of pelletized, 15N-labeled Spirulina algae. Oversight
of mouse care and procedures was provided by the University of British
Columbia Committee on Animal Care and by the Scripps Research Institute
Animal Care and Use Committee. For these first-level comparisons, palmi-
toyl-proteins were prepared by ABE purification from a 1:1 mixing of whole
brain homogenates from the individual mutant and WT 14N test mice, each
with 15N reference mouse homogenate. Details of the ABE protocol, which
effects the exchange of thioester-linked acyl moieties for biotin tags and
then purifies the tagged palmitoyl-proteins via streptavidin-agarose binding,
are provided in the Supplemental Experimental Procedures. These ABE-
purified, 14N/15N samples were then prepared for mass spectrometry by
tris(2-carboxyethyl)phosphine reduction, iodoacetamide alkylation, and over-
night trypsinization. Samples were analyzed by MuDPIT (multidimensional
protein identification technology; Link et al., 1999; Washburn et al., 2001) on
an LTQ Orbitrap XL instrument (Thermo Finnigan; for details, see Supple-
mental Experimental Procedures). Tandem mass spectra were searched
against combined light (14N) and heavy (15N) versions of the EBI-IPI mouse
protein database (EBI-IPI_mouse_01-01-09), with each identified peptide
being subsequently matched to either its heavy or light counterpart peptide
by Census, a software suite designed for quantitative analysis of MS/MS
data from stable-isotope-labeled samples (Park et al., 2008). In brief, for
each identified 14N or 15N peptide, Census constructs a chromatogram
from the MS1 data and then, based on the predicted 14N and 15N peptide
mass differences, it finds theMS1 peak for the counterpart peptide. A compar-
ison of 14N and 15N peak volumes yields a 14N/15N ratio for each identified
peptide, essentially a datapoint reporting on the relative abundance of the
associated palmitoyl-protein in test and reference brain. Abundant palmi-
toyl-proteins typically are identified by multiple peptides per MS/MS run
and, thus, multiple datapoints. As described above (see Results), our analysis
has largely focused on the 300 palmitoyl-proteins identified, on average, by
five or more quantifiable peptides per MS/MS run. The comparison of interest,
the comparison of individual palmitoyl-protein abundance levels within the
mutant palmitoyl-proteome with levels within the isogenic WT palmitoyl-
proteomes, is then derived via a ratio of ratios approach, which compares
the median 14N/15N peptide ratio from mixed 14N/15N mutant samples
with the median ratio derived from the WT sample. For the Hip14-gt analysis,
a total of eight samples were analyzed: four 14N/15N samples analyzed each
forHip14-gt and forWT littermatemice, corresponding to three individual mice
plus one technical replicate for each genotype. The YAC128 relied on the
analysis of four YAC128 brains and two WT littermate brains.
Data Sharing
RAW files and complete parameter files will be publically available at http://
fields.scripps.edu/published/ABE_SILAM upon publication.
Antibodies and Immunoblot Quantification
See Supplemental Experimental Procedures.
Analysis of Substrate Specificity in Yeast
For this analysis, which assessed the palmitoylation activity of twomammalian
DHHC PATs, HIP14 and DHHC5, against several potential mammalian sub-
strates, namely Snap25, Flot1, and Flot2, cDNAs both for the PATs and for
the substrate proteins were subcloned as epitope-tagged constructs into
appropriate yeast expression vectors, allowing their coexpression in yeast
cells. Substrate protein palmitoylation was assessed via a click-labeling
protocol (Charron et al., 2009; Roth et al., 2011), for which cultured, coex-
pressing yeast cells were metabolically labeled with the alkynated palmitateChemistry & Biology 20, 1421–143analog 17-octadecynoic acid (ODYA; Cayman Chemical). Subsequently,
extracts were prepared, allowing PAT and substrate proteins to be purified
by immune precipitation and then click-reacted with Alexa Fluor 647 Azide
(Life Technologies). Palmitoylation then was assessed by SDS-PAGE followed
by fluorography. Details of both the plasmid constructions and the click
labeling are provided in the Supplemental Experimental Procedures.
Acyl-RAC-Based Analysis and Palmitoylation Stoichiometry
As detailed in the Supplemental Experimental Procedures, a modified acyl-
RAC protocol (Forrester et al., 2011) was used both to confirm palmitoylation
of several proteins identified by the ABE/SILAM analysis and to examine frac-
tional palmitoylation status for selected individual proteins. The starting points
for both analyses were whole brain homogenates deriving from 3-month-old
WT mice (i.e., the f1 progeny from a C3H 3 C57Bl/6 cross).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2013.09.018.
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